Results 131 to 140 of about 44,864 (262)

Identifying a Csmd3+ Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma

open access: yesAdvanced Science, EarlyView.
The study establishes an immune‐cure (ICu) mouse model based on a TMEMed G422TN‐GBM system that faithfully recapitulates human TMEMed GBM. scRNA‐seq analysis reveals a Csmd3+ microglial subset with innate immune memory (IIM) potential that potently suppresses GBM growth, drives a TME cold‐to‐hot transition, and induces 100% ICu in long‐term survival ...
Hai‐Feng Jiang   +12 more
wiley   +1 more source

Deciphering Anti‐Cancer Drug Efficacy Through Nanomechanical Vibrations in Living Gastric Cancer Organoids

open access: yesAdvanced Science, EarlyView.
This study developed an efficacy assessment platform that integrates patient‐derived gastric cancer organoids, atomic force microscopy (AFM)‐based nanomechanical vibration detection, deep learning analysis, and organoid mechanical modeling. It detects picomolar drug effects within 0.1 s signal, achieves 97% classification accuracy, and offers non ...
Ting Zhang   +10 more
wiley   +1 more source

Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer. [PDF]

open access: yesCell Commun Signal
Lee IT   +6 more
europepmc   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

open access: yesAdvanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu   +12 more
wiley   +1 more source

Next-generation immunotherapy biologics for glioblastoma. [PDF]

open access: yesFront Immunol
Schonfeld E   +8 more
europepmc   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

open access: yesAdvanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan   +9 more
wiley   +1 more source

First Case of TAP1 Deficiency with EBV B-Cell Lymphoma Treated with Cellular Immunotherapy. [PDF]

open access: yesJ Clin Immunol
Bermejo-Olivera FJ   +12 more
europepmc   +1 more source

Sonoselective Transfection of Glioma Endothelium

open access: yesAdvanced Science, EarlyView.
Delivering non‐viral, gene‐bearing nanoparticles with thiol‐decorated surfaces to gliomas with focused ultrasound yields transfection tropism for endothelial cells. From this platform, “sonoselective” transfection of glioma endothelium is achieved via incorporation of an endothelial cell‐specific promoter.
Anna C. Debski   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy